Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis (Q33982025)

30 July 2017

title

Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis (English)

1 reference

30 July 2017

main subject

Pseudomonas aeruginosa

0 references

cystic fibrosis

0 references

multiple drug resistance

1 reference

Mirakhur A

1

1 reference

30 July 2017

Gallagher MJ

2

1 reference

30 July 2017

Ledson MJ

3

1 reference

30 July 2017

Hart CA

4

1 reference

30 July 2017

Walshaw MJ

5

1 reference

30 July 2017

publication date

1 March 2003

1 reference

Journal of Cystic Fibrosis

30 July 2017

published in

1 reference

30 July 2017

volume

2

1 reference

30 July 2017

issue

1

1 reference

30 July 2017

page(s)

19-24

1 reference

Emergence of antibiotic resistance amongst Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Oxidant mechanisms in gentamicin nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Spread of beta-lactam-resistant Pseudomonas aeruginosa in a cystic fibrosis clinic.

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Phosphonomycin, a New Antibiotic Produced by Strains of Streptomyces

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Antimicrobial activity of fosfomycin in vitro.

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Pharmacokinetic comparison between fosfomycin and other phosphonic acid derivatives

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Fosfomycin: Absorption and Excretion

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Pharmacokinetics of fosfomycin

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

The mechanism of action of fosfomycin (phosphonomycin)

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Fosfomycin trometamol

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Protective effect of fosfomycin on the experimental nephrotoxicity induced by dibekacin

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Mechanism of protective effect of fosfomycin against aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Protective effect of fosfomycin against aminoglycoside ototoxicity

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Establishment of aging biofilms: possible mechanism of bacterial resistance to antimicrobial therapy

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

The role of the microcolony mode of growth in the pathogenesis of Pseudomonas aeruginosa infections.

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

A sandwich cup method for the penetration assay of antimicrobial agents through Pseudomonas exopolysaccharides

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Combination effect of fosfomycin and ofloxacin against Pseudomonas aeruginosa growing in a biofilm

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Synergy of ciprofloxacin with fosfomycin in vitro against Pseudomonas isolates from patients with cystic fibrosis.

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

In-vitro activity of the combination of ceftriaxone and fosfomycin against staphylococci

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Synergistic activities of combinations of beta-lactams, fosfomycin, and tobramycin against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Interactions of fosfomycin with other antibiotics

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

In vitro activity of fosfomycin combined with ceftazidime, imipenem, amikacin, and ciprofloxacin against Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Fosfomycin: Laboratory Studies

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Mode of protective action of fosfomycin against dibekacin-induced nephrotoxicity in the dehydrated rats

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

A general practitioner multicenter study: fosfomycin trometamol single dose versus pipemidic acid multiple dose.

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

An open study of the efficacy and safety of single dose fosfomycin trometamol in treatment of hospitalised patients with urinary tract infection (pilot study).

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?

1 reference

https://api.crossref.org/works/10.1016/S1569-1993(02)00143-1

7 January 2021

10.1016/S1569-1993(02)00143-1

Identifiers

DOI

1 reference

30 July 2017

1 reference